论文部分内容阅读
In order to develop a desirable inexpensive,effective and safe vaccine against the very virulentinfectious bursal disease virus (vvIBDV),we tried to take advantage of the emerging T4 bacteriophagesurface protein display system.The major immunogen protein VP2 from the vvlBDV strain HK46 wasfused to the nonessential T4 phage surface capsid protein,a small outer capsid (SOC) protein,resulting inthe 49 kDa SOC-VP2 fusion protein,which was verified by sodium dodecylsulfate polyacrylamide gelelectrophoresis and Western blot.Immunoelectromicroscopy showed that the recombinant VP2 protein wassuccessfully displayed on the surface of the T4 phage.The recombinant VP2 protein is antigenic and showedreactivities to various monoclonal antibodies (mAbs) against IBDV,whereas the wild-type phage T4 couldnot react to any mAb.In addition,the recombinant VP2 protein is immunogenic and elicited specific antibodiesin immunized specific pathogen free (SPF) chickens.More significantly,immunization of SPF chickenswith the recombinant T4-VP2 phage protected them from infection by the vvIBDV strain HK46.Whenchallenged with the vvIBDV strain HK46 at a dose of 100 of 50% lethal dose (LD_(50)) per chicken 4 weeksafter the booster was given,the group vaccinated with the T4-VP2 recombinant phage showed no clinicalsigns of disease or death,whereas the unvaccinated group and the group vaccinated with the wild-type T4phage exhibited 100% clinical signs of disease and bursal damages,and 30%—40% mortality.Collectively,the data herein showed that the T4-displayed VP2 protein might be an inexpensive,effective and safe vaccinecandidate against vvIBDV.
In order to develop a promising inexpensive, effective and safe vaccine against the very virulent infectious bursal disease virus (vvIBDV), we tried to take advantage of the emerging T4 bacteriophagesurface protein display system. Major immunogen protein VP2 from the vvlBDV strain HK46 wasfused to the nonessential T4 phage surface capsid protein, a small outer capsid (SOC) protein, resulting inthe 49 kDa SOC-VP2 fusion protein, which was verified by sodium dodecylsulfate polyacrylamide gelelectrophoresis and Western blot. Immunoelectromicroscopy showed that the recombinant VP2 protein wassuccessfully displayed on the surface of the T4 phage. recombinant VP2 protein is antigenic and showed reactivities to various monoclonal antibodies (mAbs) against IBDV, and the wild-type phage T4 could not react to any mAb. addition, the recombinant VP2 protein is immunogenic and elicited specific antibodies in immunized specific pathogen free (SPF) chickens. More significantly, immunization of SPF chic kenswith the recombinant T4-VP2 phage protected them from infection by the vvIBDV strain HK46. Invasive challenge with the vvIBDV strain HK46 at a dose of 100 of 50% lethal dose (LD_ (50)) per chicken 4 weeksafter the booster was given, the group vaccinated with the T4-VP2 recombinant phage showed no clinicals of disease or death, and the unvaccinated group and the group vaccinated with the wild-type T4phage exhibited 100% clinical signs of disease and bursal damages, and 30% -40% mortality. Collectively , the data indicates showed that the T4-displayed VP2 protein might be an inexpensive, effective and safe vaccine match and against vvIBDV.